文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

树枝状聚合物纳米疗法治疗重症COVID-19可减轻炎症和神经损伤标志物并改善2a期临床试验结局

Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial.
PubMed 文献 · Sci Transl Med · 2022-07-20

这项多中心、随机、双盲、安慰剂对照、适应性2a期试验评估了OP-101在重症COVID-19患者中的安全性和初步疗效;24例基线WHO七分类量表≥5分的患者随机接受单次静脉安慰剂或OP-101 2、4、8 mg/kg,所有患者均接受包括皮质类固醇的标准治疗;OP-101 4 mg/kg在降低炎症标志物方面优于安慰剂,4和8 mg/kg在降低神经损伤标志物方面优于安慰剂;30天和60天机械通气或死亡复合结局风险安慰剂组为71%(95%CI:29%,96%),汇总OP-101治疗组为18%(95%CI:4%,43%;P=0.021)。

要点

  • OP-101 4 mg/kg在降低炎症标志物方面优于安慰剂。
  • OP-101 4和8 mg/kg在降低神经损伤标志物方面优于安慰剂。
  • 30天和60天机械通气或死亡复合结局风险安慰剂组71% vs 汇总OP-101组18%(P=0.021)。

核心结论

  • OP-101耐受性良好,可能具有治疗全身性炎症和神经元损伤的潜力,降低重症COVID-19住院患者的发病率和死亡率。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、适应性2a期临床试验。
  • 24例重症COVID-19且基线WHO七分类量表≥5分的患者随机接受单次静脉安慰剂(n=7)或OP-101 2 mg/kg(n=6)、4 mg/kg(n=6)、8 mg/kg(n=5)。
  • 所有受试者均接受包括皮质类固醇的标准治疗。

主要发现

  • OP-101 4 mg/kg在降低炎症标志物方面优于安慰剂。
  • OP-101 4和8 mg/kg在降低神经损伤标志物(神经丝轻链和胶质纤维酸性蛋白)方面优于安慰剂。
  • 治疗后30天和60天机械通气或死亡复合结局风险:安慰剂组71%(95%CI:29%,96%),汇总OP-101治疗组18%(95%CI:4%,43%;P=0.021)。
  • 60天时,安慰剂组7例中3例存活,OP-101治疗组17例中14例存活。
  • 未报告药物相关不良事件。

关键数值与推荐

  • 重症COVID-19定义为基线WHO七分类量表≥5分。
  • OP-101剂量为单次静脉2、4或8 mg/kg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperinflammation triggered by SARS-CoV-2 is a major cause of disease severity, with activated macrophages implicated in this response. OP-101, a hydroxyl-polyamidoamine dendrimer-N-acetylcysteine conjugate that specifically targets activated macrophages, improves outcomes in preclinical models of systemic inflammation and neuroinflammation. In this multicenter, randomized, double-blind, placebo-controlled, adaptive phase 2a trial, we evaluated safety and preliminary efficacy of OP-101 in patients with severe COVID-19. Twenty-four patients classified as having severe COVID-19 with a baseline World Health Organization seven-point ordinal scale of ≥5 were randomized to receive a single intravenous dose of placebo (n = 7 patients) or OP-101 at 2 (n = 6), 4 (n = 6), or 8 mg/kg (n = 5 patients). All study participants received standard of care, including corticosteroids. OP-101 at 4 mg/kg was better than placebo at decreasing inflammatory markers; OP-101 at 4 and 8 mg/kg was better than placebo at reducing neurological injury markers, (neurofilament light chain and glial fibrillary acidic protein). Risk for the composite outcome of mechanical ventilation or death at 30 and 60 days after treatment was 71% (95% CI: 29%, 96%) for placebo and 18% (95% CI: 4%, 43%; P = 0.021) for the pooled OP-101 treatment arms. At 60 days, 3 of 7 patients given placebo and 14 of 17 OP-101-treated patients were surviving. No drug-related adverse events were reported. These data show that OP-101 was well tolerated and may have potential to treat systemic inflammation and neuronal injury, reducing morbidity and mortality in hospitalized patients with severe COVID-19.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Gusdon AM, Faraday N, Aita JS, et al. Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. Sci Transl Med. 2022. PMID: 35857827. doi:10.1126/scitranslmed.abo2652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。